TransMedics Q1 revenue edges past estimates

TransMedics

05/05/2026 21:30

Overview

US organ transplant tech firm's Q1 revenue rose 21%, slightly beating analyst expectations

Adjusted EPS for Q1 fell from prior year as operating expenses increased

Company reiterated full-year 2026 revenue guidance of $727 mln to $757 mln

Outlook

TransMedics reiterates 2026 revenue guidance of $727 mln to $757 mln

Company expects 20% to 25% revenue growth for full yr 2026

TransMedics says ongoing investment in clinical programs and logistics to drive growth

Result Drivers

OCS UTILIZATION - Co said revenue growth was primarily due to increased use of the Organ Care System, especially in liver and heart transplants through the National OCS Program, and higher logistics services revenue

HIGHER OPERATING COSTS - Gross margin declined mainly due to investments to support growth and scale, and higher supply chain and operating costs

R&D AND ORGANIZATIONAL SPENDING - Operating expenses increased, driven by higher research and development investment and spending across the organization to support growth

Company press release: ID:nPn1dTHJ9a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Slight Beat*
$173.90 mln
$172.64 mln (9 Analysts)
Q1 EPS
$0.20
Q1 Net Income
$7.30 mln
Q1 Gross Margin
58.00%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Transmedics Group Inc is $157.00, about 61.7% above its May 4 closing price of $97.08

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)